Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Eli Lilly and CompanyNYSE: LLY

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows, but more slowly than its trailing trend

Q2 FY2026 EBITDA of $12.99B rose 73.2% year over year, behind the +103.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 26.3% from the prior quarter. Over 3 fiscal years it compounded at +54.1% a year.

Context

  • EBITDA amounted to 48.6% of revenue in FY2025, up 6.9 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 18 analysts of $41.34B (+30.4%) for the fiscal year ending Dec 2026, a slowdown from the +68.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.99B+26.3% QoQ
Last fiscal yearDec 2025
$31.69B+68.5% YoY
LTMJun 2026
$43.3B+103.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.2%-12.3%-85.6 pp
1 year+68.5%+30.4%-38.1 pp
3-year CAGR+54.1%+28.6%-25.5 pp
5-year CAGR+22.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
31.69B USD
Year-over-year change
+68.5%
4-year CAGR
+40.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +103.7% is the highest of 10, against a peer median of +4.7%.
  • EBITDA amounts to 54.4% of revenue for LLY, versus a peer median of 34.4%.
LLY Competitors
EBITDA for LLY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 180.91B DKK+4.7%+26.8%54.9%
LLYEli Lilly and CompanyLTM Jun 2026$43.3B USD+103.7%+54.1%54.4%
JNJJohnson & JohnsonLTM Sep 2026$30.81B USD-22.1%+15.6%31.0%
ABBVAbbVie Inc.LTM Sep 2026$24.15B USD+88.7%-10.0%36.6%
NVSNovartis AGLTM Jun 2026$22.26B USD-2.0%+16.1%40.0%
AZNAstraZeneca PLCLTM Sep 2026$21.37B USD+18.6%+29.7%34.4%
AMGNAmgen Inc.LTM Jun 2026$17.62B USD+10.8%+11.6%46.2%
SNYSanofiLTM Jun 2026€14.77B EUR+15.5%-2.6%30.2%
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
Peer median (excluding LLY) —+4.7%+11.6%34.4%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.32B28.54B34.12B45.04B65.18B
Cost of Revenue7.31B6.63B7.08B8.42B11.05B
Gross Profit21.01B21.91B27.04B36.63B54.13B
Gross Margin74.2%76.8%79.2%81.3%83.0%
Research & Development6.93B7.19B9.31B10.99B13.34B
Selling, General & Admin6.14B6.07B6.94B8.59B11.09B
Operating Expenses13.07B13.26B16.25B19.59B24.43B
Depreciation & Amortization1.55B1.52B1.53B1.77B2B
EBITDA8.04B8.66B8.57B18.81B31.69B
EBITDA Margin28.4%30.3%25.1%41.8%48.6%
Operating Income7.93B8.65B10.79B17.04B29.7B
Operating Margin28.0%30.3%31.6%37.8%45.6%
Interest Income25.4M62.8M173.6M175.2M153.3M
Interest Expense339.8M331.6M485.9M780.6M795.3M
Other Income / Expenses(1.78B)(1.85B)(4.23B)(4.36B)(3.97B)
Income Before Tax6.16B6.81B6.55B12.68B25.73B
Pre-Tax Margin21.7%23.8%19.2%28.2%39.5%
Income Tax Expense573.8M561.6M1.31B2.09B5.09B
Net Income5.58B6.24B5.24B10.59B20.64B
Net Margin19.7%21.9%15.4%23.5%31.7%
EPS (Basic)5.856.575.8311.7623.07
EPS (Diluted)5.856.575.8011.7122.95
Weighted Avg Shares953.65M950.18M899.38M900.61M898M
Weighted Avg Shares (Diluted)953.65M950.18M903.28M904.06M898M

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.